
    
      In response the the already commented on, the purpose of this one armed, phase II trial is to
      determine the efficacy and safety profile of a hypofractionated radiotherapy regimen, 16 Gy
      in 2 fractions with an interval of one week, for the palliation of complicated bone
      metastases in patients with poor performance status.
    
  